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Abstract
Introduction: Type 1 diabetes is an insulin deficiency-based chronic disease. It leads to the development of hyperglycaemia, 
which plays a key role in the initiation and progression of tissue damage in patients with diabetes. This mostly results from 
oxidative stress, whose increased severity is observed in this group of patients. Increased levels of 8-isoprostanes are seen in 
many inflammatory diseases, including asthma, COPD and cystic fibrosis. In these diseases it was demonstrated exhaled breath 
condensate (EBC) is useful for extracting material for markers of oxidative stress, including 8-isoprostanes. The purpose of this 
study was to assess the severity of oxidative stress measured with 8-isoprostane concentrations in the exhaled breath conden-
sate in healthy subjects and in patients with type 1 diabetes with and without vascular complications.
Material and methods: 33 patients assigned to the control group, type 1 diabetes without complications group and type 1 diabe-
tes group with advanced complications were included in the study. Retinopathy, nephropathy or neuropathy have been reported 
as a criterion distinguishing between complicated and uncomplicated diabetes. EBC was obtained for each subject. 8-isoprostane 
concentrations were determined in serum and EBC by ELISA.
Results and conclusions: Mean (± SD) blood levels of 8-isoprostane in patients with type 1 diabetes mellitus without compli-
cations and those with type 1 diabetes with advanced complications were significantly higher compared to the control group 
(178.17 [135.73] vs. 183.34 [200.41] vs. 47.13 [25.20] pg/ml; p < 0.05). The mean (± SD) concentration of 8-isoprostane in EBC 
was lower in diabetic patients with type 1 diabetes with advanced complications than in patients with type 1 diabetes without 
advanced complications and in the control group (8.32 [4.60] vs. 19.13 [22.35] vs. 28.17 [35.11] pg/ml; p < 0.05). Measurement 
of 8-isoprostanes in the EBC in patients with type 1 diabetes does not appear to be a good diagnostic tool for monitoring the 
activity of oxidative stress in these patients.
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Introduction
Type 1 diabetes is an insulin deficiency-based 
chronic disease. It leads to the development of 
hyperglycaemia, which plays a key role in the 
initiation and progression of tissue damage in 
patients with diabetes [1]. This mostly results 
from oxidative stress, whose increased severity 
is observed in this group of patients [2].
Oxidative stress is a phenomenon present 
in properly functioning living organisms. Its ex-
cessive exacerbation can lead to adverse effects 
such as damage to cellular structures and DNA, 
and may consequently affect the development of 
various diseases, including cancer [3]. One of the 
tools used to determine the severity of oxidative 
stress involves the measurement of the 8-isopros-
tane concentration that results from non-enzymat-
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ic lipid peroxidation accompanied by free radicals 
[4, 5]. Increased levels of 8-isoprostanes are seen 
in many inflammatory diseases, including asthma 
[6], COPD [7] and cystic fibrosis [8]. In these dis-
eases In these demonstrated, that EBC is useful for 
extracting material for markers of oxidative stress, 
including 8-isoprostanes. The ease of obtaining 
material during EBC testing and non-invasive and 
extensive safety profiles continue to encourage 
further exploration of this research method.
The purpose of this study was to assess the 
severity of oxidative stress measured with 8-iso-
prostane concentrations in the exhaled breath 
condensate in healthy subjects and in patients 
with and without vascular complications.
According to the author’s knowledge, this is 
the first work in which oxidative stress in type 1 
diabetes was measured by the concentration of 
8-isoprostanes in the exhaled breath condensate. 
Material and methods 
Thirty three patients assigned to the control 
group, type 1 diabetes without complications 
group and type 1 diabetes group with advanced 
complications were included in the study. The 
subjects included in the study were recruited 
from the Diabetes Outpatient Clinic of the Uni-
versity Clinical Hospital No. 1 in Łódź.
The control group consisted of 12 healthy 
persons randomly selected among the staff of the 
University Clinical Hospital No. 1 in Łódź. 
The control group excluded patients with:
— Any type of diabetes
— Incorrect glucose metabolism, defined as 
abnormal fasting plasma glucose
— Smoking history, chronic pulmonary disease and 
other chronic diseases and metabolic disorders
— Familial type 1 diabetes
The criteria for inclusion in the study includ-
ed the following:
— Documented type 1 diabetes with a duration 
of not less than 15 years.
— Incorrect metabolic rate of diabetes, assessed 
basing on 3 historical concentrations of gly-
cated haemoglobin (HbA1c).
— Diabetes treated with a model of intensive 
insulin therapy.
— Non-smoking.
— No history of chronic lung disease.
The research was approved by the Bioethics 
Committee at the Medical University of Łódź. All 
participants have signed a conscious and volun-
tary agreement to participate in the study. Once 
selected, anthropometric parameters (body mass 
and height) were determined. Retinopathy, ne-
phropathy or neuropathy have been reported as a 
criterion distinguishing between complicated and 
uncomplicated diabetes. The presence of diabetic 
retinopathy was verified on the basis of ophthal-
mic examination of the fundus by means of the 
Volk 90D lens, after the pupil dilatation with the 
atropine, always performed by the same physician. 
The value of the albumin/creatinine index 
(ACR) was calculated for each subject as the ba-
sis of renal complications. Basing on the results 
thereof, the patient was assigned to the no renal 
complication group (ACR < 30 mg/g) or to ad-
vanced renal disease (ACR ≥ 30 mg/g) [9].
Medical history was used to assess neurop-
athy; a temperature and touch sensation study, 
and a tendon reflex assessment were performed.
The following laboratory tests: morphology, 
lipidogram, urea, creatinine, electrolytes, alanine 
aminotransferase and aspartate aminotransferase 
were made for a more accurate assessment of health 
status. All studies were performed at the Hospi-
tal Laboratory of the University Hospital No. 1 
in Łódź. On the same day, EBC was obtained for 
each patient by means of the EcoScreen con-
denser (Jaeger). Each of the subjects was asked to 
calmly breathe for 10 minutes using a condenser. 
Table 1. Characteristics of groups
Patients with no complications 
(n = 10)
Patients with complications  
(n = 11)
Control  
(n = 12)
Sex (M/F) 3/7 5/6 2/10
Age median (years/min.–max.) 31/19–55 49/26–70 34/25–60
Mean BMI/SD 24.0/3.4 26.6/4.5 24.4/1.6
Median of disease duration  
(years/min.–max.)
21/15–25 24/20–36 N/A
Mean HbA1c (%/SD) 8.2/1.6 8.5/1.4 5.5/0.2
BMI ― body mass index; SD ― standard deviation
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The resulting material was frozen at –80 ° C for 
further analysis.
8-isoprostane concentrations were deter-
mined in serum and EBC by ELISA using 8-iso-
prostane ELISA Kit (Cayman Chemical; Ann 
Arbor, MI, USA). The results were read by means 
of EL808 IU (BioTek; Winooski, VT, USA). 
STATISTICA version 12.0 (StatSoft Inc.) li-
cense number JPZP601E504326AR-9 was used to 
perform statistical calculations. The normality of 
distribution of empirical variables was assessed by 
graphic analysis of histograms drawn from collected 
data and by the Shapiro-Wilk test. This method was 
used for the part of the data for which the normality 
of the distribution has been demonstrated, and the 
other requirements used for the analysis of variance 
(ANOVATM) have been met. Data that did not show 
normal distribution even after transformations 
were analysed using the Kruskal-Wallis test. For 
multiple comparisons, the Least Significant Differ-
ence (LSD) test was used. Whenever the calculated 
probability coefficient p was less than 0.05, the 
result was considered statistically significant.
Results
Mean (± SD) blood levels of 8-isoprostane 
in patients with type 1 diabetes mellitus without 
complications and those with type 1 diabetes with 
advanced complications were significantly higher 
compared to the control group (178.17 [135.73] 
vs. 183.34 [200.41] vs. 47.13 [25.20] pg/ml; 
p < 0.05) — graphic illustration of the result is 
shown in Figure 1.
The mean (± SD) concentration of 8-isopro-
stane in EBC was lower in diabetic patients with 
type 1 diabetes with advanced complications 
than in patients with type 1 diabetes without 
advanced complications and in the control group 
(8.32 [4.60] vs. 19.13 [22.35]. 28.17 [35.11] pg/ml; 
p < 0.05) — graphic illustration of the result is 
presented in Figure 2. We did not manage to de-
monstrate the correlation of the variables tested.
Discussion
The decision to choose type 1 diabetes pa-
tients was not accidental. This is a group of pa-
tients particularly exposed to the development of 
complications from an early age, and angiopathy 
affects all vessels, including those in the pulmo-
nary circulation. Therefore, the usefulness of 
non-invasive methods (EBC) in assessing the se-
verity of oxidative stress in this group of patients 
seems to be an interesting issue.
–50
0
50
100
150
200
250
300
350
400
8
-i
s
o
p
ro
s
ta
n
e
 p
la
s
m
a
 c
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
 
Complications (–) Complications (+) Control group 
Mean
Mean (± SE)
Mean (±  SD)
–10
0
10
20
30
40
50
60
70
8
-i
s
o
p
ro
s
ta
n
e
 E
B
C
 c
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
 
Complications (–) Complications (+) Control group 
Mean
Mean (± SE)
Mean (±  SD)
Figure 1. Box and whisker diagram of mean plasma concentrations of 
8-isoprostanes in patients
Figure 2. Box and whisker diagram of mean plasma concentrations 
of 8-isoprostanes in EBC
The mean concentration of 8-isoprostanes 
was the highest in plasma in type 1 diabetic 
patients with developed complications. Lower 
levels of this marker were characteristic of a group 
with no developed complications. The lowest 
values were observed in the control group. These 
results appear to be consistent with the intui-
tively expected values, providing a biochemical 
evidence that the 8-isoprostane concentration is 
significantly higher in the plasma of inflammatory 
patients. Similar observations come from, among 
others, the work of Vessby [10].
Surprising results were obtained from the 
exhaled breath condensate analysis, where the 
highest concentrations of 8-isoprostanes were 
observed in the control group. This suggests that 
there may be no localised oxidative stress in the 
altered pulmonary vascular endothelium. This 
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simple explanation, however, is in contradiction 
with the observed increase in the concentration of 
methyl nitrate in the EBC and  with the increase 
in glucose levels in blood in patients with type 1 
diabetes [11]. A similar observation suggesting 
an increase in oxidation and reduction in pul-
monary vessels in diabetes was demonstrated in 
the animal model. It has been observed that the 
concentration of ethane, which is one of the lipid 
peroxidation products, is higher in the air exhaled 
in both acute and chronic hyperglycaemic rats 
[12]. The mechanism of diffusion of 8-isoprosta-
nes from the blood into the lung follicles is not 
fully understood. Certainly, any structural change 
in this pathway may result in changes in EBC 
compound concentrations, which, in the context 
of observed basophilic thickening of the membra-
ne in patients with diabetes [1, 13–18], seems to 
be a reasonable explanation for our observations.
Because the research problem has not been 
studied so far, the results we have obtained need 
to be confirmed in subsequent scientific studies.
Conclusions
1.  Type 1 diabetes is accompanied by increased 
oxidative stress manifested by increased lipid 
peroxidation, measured by plasma concen-
trations of 8-isoprostanes.
2.  The highest plasma levels of 8-isoprostanes 
are noted in patients with type 1 diabetes 
with advanced complications.
3.  The concentration of 8-isoprostanes in the 
EBC of patients with type 1 diabetes is lower 
compared to healthy subjects.
4.  Measurement of 8-isoprostanes in the EBC in 
patients with type 1 diabetes does not appear 
to be a good diagnostic tool for monitoring the 
activity of oxidative stress in these patients. 
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